James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.
“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”
Wall Street Journal, November 23
Power List Methodology The power lists are compiled by the NJBIZ editorial staff based on our reporting throughout the past year with input from experts in a variety of fields and recommendations from our readers. The staff looks for people who have gained public...
By Leigh Ann Von Hagen., Analise Draghi & Greg Woltman Across New Jersey, communities are embracing faster, more flexible ways to make streets safer. Demonstration projects are short-term, low-cost installations that test street design changes. They have become a...
Abstract An assembly of literature finds that the Home Owners' Loan Corporation (HOLC) did not engage in credit redlining, by means of withdrawing mortgage refinance support from lower rated areas and extensively directing support to higher rated areas. The HOLC does...
What does Port Newark/Elizabeth have to do with your morning glass of OJ? On Friday, April 10 Bloustein graduate students in Professor Anne Strauss Wieder's Freights & Ports class again took their learning beyond the classroom and straight to the docks to see...
Coleridge recently presented its Data Champion of the Year Award for 2026 to the State of New Jersey. The award recognizes exceptional leadership in advancing trust, collaboration, and the effective use of data to improve public outcomes. The award was presented to...